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Abstract: It is widely recognized that the incidence of allergies and
allergic diseases is on the rise globally. As an international umbrella
organization for regional and national allergy and clinical immunol-
ogy societies, the World Allergy Organization is at the forefront of a
combined united effort across nations and organizations to address
this global concern by promoting the science of allergy and clinical
immunology, and advancing exchange of information.
The World Allergy Organization’s State of World Allergy Reports
will provide a biennial review of allergic diseases worldwide, consider
their medical and socioeconomic contexts, and propose effective
approaches to addressing these problems.
In this ﬁrst State of World Allergy Report 2008, experts from
different regions of the world have attempted to deﬁne the extent of
the global allergy problem, examine recent trends, and provide a
framework for the collaboration among world medicine, science, and
government agencies that is needed to address the rapidly developing
issues associated with allergy and allergic diseases.
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W hat may have begun as a crucial species-protectingimmune defense against parasites in humans is now
ironically responsible for one of the most common maladies,
allergy, which contributes to massive deﬁcits in quality of life
and, in some cases, length of life.
Allergy represents an immune programming error.
Immunoglobulin E is normally protective against many para-
sites, but can also cause the release of histamine and other
chemical mediators on exposure to otherwise benign proteins
present in airborne pollens, molds, animal danders, and food.
Does immunoglobulin E confuse the complex DNA code in
these proteins with those of its primary target, parasites? Evo-
lutionary adaptationists argue that the human immune system
may be calibrated to a certain parasitic load: when that parasite
burden decreases as society eliminates parasitosis through
public health measures, the immune system may become
excessively sensitive and respond defensively to harmless
substances because of a state of confusion. Exacerbated by an
increased exposure to sensitizing allergens, this confusion is
manifested through allergic diseases such as asthma, rhino-
conjunctivitis, atopic eczema, urticaria, and anaphylaxis.
The current scientiﬁc consensus is that higher standards
of hygiene may deprive the developing immune response
of important immunologic signals during the period from
birth to six years, signals that are important for steering the
lifelong direction of the immune system response. This
hygiene hypothesis, Holgate1 argues, Bbest accommodates
the link between allergy and social class, the urban to rural
gradient, infant diet, overuse of antibiotics, and the East toWest
gradient of disease.[
Thus, in the zeal to improve standards of health and
reduce infectious disease, the world may be discovering that
improved living conditions along with the rapid industrializa-
tion of developing nations and a changing world climate pre-
sent opportunities, challenges, and complexities for human
health that have never before been considered. Allergic
diseases are increasing in prevalence worldwide and are now
the most frequent reasons patients seek medical care. Allergies
are also becoming more complex, and patients frequently have
multiple allergic disorders. Even the less severe allergic dis-
eases can have a major adverse effect on the health of hun-
dreds of millions of patients and diminish quality of life and
work productivity. Allergy is a major problem for the 21st
century, and this problem is predicted to worsen as this century
moves forward.
As the incidence of allergy and associated diseases has
increased, the number of health care professionals trained in the
diagnosis and treatment of allergy has decreased. As a result,
untold numbers of patients go undiagnosed or are undertreated.
Many developing countries have few or no allergy-trained
physicians to treat millions of allergy and asthma sufferers, and
even in developed countries, many highly sophisticated areas
have no trained allergists.
The best response to these issues is for the community of
world allergists to promote better the science of allergy and
clinical immunology and the exchange of information. The
World Allergy Organization is at the forefront of attempts to
understand, address, and respond to these issues.
In this ﬁrst State of World Allergy Report, experts from
different regions of the world have attempted to deﬁne the
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extent of the problem, examine recent trends, and provide a
framework for the collaboration of world medicine, science,
and government agencies that is needed to address the rapidly
developing issues associated with allergy and chronic
respiratory disease.
The report opens with a review of the state of allergy and
common chronic allergic respiratory diseases in the Asia-
Paciﬁc region, which hosted the World Allergy Congress in
Bangkok in December 2007 (where this report was ﬁrst
announced). The Asia-Paciﬁc region is also the most populous
region of the world and encompasses many highly developed
nations and numerous emerging economies. A signiﬁcant
increase in the prevalence of allergies in the emerging societies
of this region is anticipated as the social and economic
environments change to more industrial and postindustrial
infrastructures. An overview of the global epidemiology of
allergic diseases in the following section provides information
on world trends and contrasts the current situation between
developed nations and developing economies. The report next
outlines the active response to the growing problem of allergic
diseases by two major world organizations: the World Allergy
Organization and the Global Alliance against Chronic Res-
piratory Diseases of theWorld Health Organization. The report
concludes with speculation about the changing environmental
and social factors that are expected to inﬂuence the future
global pattern of allergic diseases and considers the resources
that will be needed to manage this burgeoning global epidemic.
The pharmaceutical industry, in its own response to this
growing problem, has for many years worked alongside the
scientiﬁc community to ensure that scientiﬁc discoveries and
innovations are put into practice in the service of allergy
patients and physicians. Recognizing the importance of this
review, members of the pharmaceutical sector are supporting
the State of World Allergy Report through an unrestricted
educational grant.
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ALLERGY AND ASTHMA: MAJOR PROBLEMS IN
THE ASIA-PACIFIC REGION
Asthma is a chronic inﬂammatory disease of the airways
that is often associated with airway hyperresponsiveness and
variable airﬂowobstruction. Asthma is usually reversible either
spontaneously or with treatment. Allergic rhinitis is an im-
munoglobulin EYmediated inﬂammation of the nasal mucosa.
Asthma and allergic rhinitis are two of the most common
chronic respiratory (airway) diseases in childhood, but both
of these diseases also affect adults. The prevalence of these
diseases increased substantially in many parts of the world
during the 20th century. Allergic sensitization, that is, the
development of speciﬁc immunoglobulin E antibodies against
common allergens, is an important risk factor for asthma, and
asthma is often associated with allergic rhinitis.
An estimated 300 million persons worldwide have
asthma, approximately 50% of whom live in developing coun-
tries with limited access to essential drugs; therefore, asthma is
often poorly controlled in these areas.1 Four hundred million
persons worldwide have allergic rhinitis.1,2
Two large international studies, the International Study
of Asthma and Allergies in Childhood (ISAAC)3 and the
European Community Respiratory Health Survey (ECRHS),4
have studied the prevalence of asthma and allergic rhinitis
worldwide through the use of standardized questionnaires.
Both the ECRHS and ISAAC have shown substantial vari-
ations in the prevalence of asthma and allergic rhinoconjuncti-
vitis across countries and regions.
ASTHMA AND ALLERGIC RHINITIS: COMORBID
CHRONIC ALLERGIC RESPIRATORY DISEASES
The ISAAC showed that in general, with some excep-
tions, higher levels of allergic rhinitis or hay fever are observed
in communities with higher levels of asthma. Up to 70% of
persons in the ECRHS who reported having asthma also
reported having hay fever, and in all centers, hay fever was
strongly associated with the presence of asthma.5 Some lon-
gitudinal studies suggest that the incidence of asthma is more
common in those with a history of rhinitis and that the risk is
greater in thosewith hay fever of the longest duration and of the
greatest severity and in those with both sinusitis and rhinitis.6
ASTHMA AND ALLERGIC RHINITIS IN THE
ASIA-PACIFIC REGION
Increasing Prevalence
Asia is the world’s most populous continent, with a pop-
ulation of almost 4 billion people and many emerging econ-
omies. According to recent epidemiological data from ISAAC
phase III, asthma and allergic rhinitis have increased in several
areas, mostly in low- and middle-income countries.7,8 The
prevalence of allergic diseases in Asia varies widely but was
found to have increased (from 0.8% to 29.1% for asthma and
from 5% to 45% for allergic rhinitis) as communities adopted
modern lifestyles and became urbanized.
Time trends in the prevalence of asthma symptoms also
showed different regional patterns, that is, a decrease in cur-
rent wheezing in children aged 13 to 14 years in western Eu-
rope and an increase in wheezing children of the same age
group in the Asia-Paciﬁc region. Even within the Asian region,
there was a wide variation among countries. The prevalence of
asthma in Japan increased from 3.5% in 1982 to 4.6% in 19929
to 9.1% in 2006 (A. Akasawa, M.D., Ph.D., unpublished data,
2006) and was accompanied by an increase in allergic rhinitis
of up to 32% (A. Akasawa, M.D., Ph.D., unpublished data,
2006). Similarly, 2 surveys performed in Taiwan using an
identical method showed that the prevalence of childhood
asthma had increased from 1.3% in 1974 to 5.07% in 1985.10
More recent ISAAC III data showed that in 13- and 15-year-
old children in Taiwan, the overall cumulative and 12-month
prevalences of wheezing and rhinitis in the younger children
were 8.2% and 44.4%, respectively, and those in the older
children were 6.9% and 42.2%, respectively.11 The percentage
of children in Singapore who had experienced asthma at least
once increased from 5.5% in 1967 to 13.7% in 1987 and to
20.7% in 1996. In Singaporean preschoolers aged 4 to 6 years,
WAO Journal & June 2008, Supplement 1 State of World Allergy Report 2008
* World Allergy Organization S5
Copyright @ 2008 World Allergy Organization. Unauthorized reproduction of this article is prohibited.
the cumulative and previous 12-month prevalences of
wheezing were 27.5% and 16.0%, respectively. Asthma was
reported by 11.7% of this group of children, and the current
prevalence of rhinitis was 25.3%.
A ﬁeld study conducted in four major cities in India with
the use of a validated questionnaire showed the overall prev-
alence of asthma in 2006 to be 2.38%.12 In a recent study
in rural Bangladesh, the prevalence of asthma in children was
16.1%.13 In contrast, in nonrural Lhasa, Tibet, the prevalences
of current wheezing and diagnosed asthma were 0.8% and
1.1%, respectively.14 The prevalence of allergic rhinoconjunc-
tivitis in Tibet was 5.2%. Even within the same country, the
prevalence of asthma differed among various populations.7,8
Although overall regional data for adults are scant, between 1%
and 10% of adults are estimated to have asthma, and between
10% and 32% are estimated to have allergic rhinitis.
Triggers and Risk Factors
Aeroallergens that trigger allergy and asthma vary from
area to area in geographically diverse Asia. Although house-
dust mites are the major triggering allergen in most of Asia,
pollens, such as Japanese cedar pollen, are a major cause of
allergic rhinitis in Japan. In a study of the prevalence of allergen
sensitization among asthma patients in Thailand, house-dust
mites (both Dermatophagoides species and Blomia tropicalis)
were the most common sensitizing allergens in both pediatric
and adult patients with asthma.15 Other important allergens, in
order of priority, were cockroach and oil palm pollen. In
contrast, less than 5% of patients were sensitive to other pollens
and spores. Similarly, in a study of the sensitization proﬁle of
the general population in Southeast Asia to house-dust mites,
subjects with rhinitis were most sensitive to B. tropicalis,
followed by Dermatophagoides pteronyssinus (73% and 50%,
respectively).16 Dual sensitization was common.
Although genetic factors are important in the manifesta-
tion of asthma and allergic rhinitis, the rapid increase in the
prevalence of these disorders cannot be attributed to genetic
factors alone. Changes in environmental factors also need to
be taken into account. In a survey that compared the preva-
lence of asthma and atopic disorders in Chinese children aged
12 to 18 years in three Asian cities (Hong Kong, Kota
Kinabalu, and San Bu, with Hong Kong being the most
developed and westernized city), the prevalence of asthma and
allergic disorders in children from Hong Kong was 2 to 6 times
that in children from the other 2 cities.17 Allergic sensitization
was a signiﬁcant factor associated with asthma. The prevalence
of atopy in Kota Kinabalu was high (64%), yet the prevalence
of asthma was low (1.9%). In a cross-sectional prevalence
analysis of wheezing, rhinitis, and eczema in Singaporean
preschoolers aged 4 to 6 years, the main risk factors for cur-
rent wheezing and self-reported asthma were family history
of allergy, concurrent rhinoconjunctivitis, concurrent chronic
ﬂexural rash, and previous respiratory tract infection.18 In rural
Bangladesh, risk factors associated with wheezing were
pneumonia (at ages 0 to 12 months and 13 to 24 months),
maternal asthma, paternal asthma, and maternal eczema.13
Despite extensive research on genetic, environmental,
and lifestyle causes of asthma and on asthma risk factorsV
including pollution, tobacco smoke, diet, urban lifestyle, re-
duced early exposure to infections, and viral infectionsVno
single factor has been identiﬁed as responsible for the marked
geographic variation in or the increasing prevalence of asthma.
Morbidity and Mortality
Patients with asthma and allergic rhinitis have a reduced
quality of life, and the burden of asthma, as assessed by
disability-adjusted life-years, ranks 22nd among all diseases
worldwide.19 Moreover, asthma in infancy often goes unrec-
ognized and thus untreated.
The Asthma Insights and Reality in Asia-Paciﬁc Study,
which looked at patient perceptions of asthma management
across Asia, concluded that patients experience frequent and
unnecessary symptoms and exacerbations because of a lack
of adequate asthma control.20 Indeed, 27% of adults and 37%
of children with asthma in the Asia-Paciﬁc region reported that
this condition had resulted in an absence from school or work
in the previous year, and 40% reported being hospitalized,
visiting the emergency department or making unscheduled
emergency visits to other health care facilities in the previous
year. The severity of asthma varied, with Vietnam and China
reporting the most patients with severe persistent symptoms.
Work absence was highest in the Philippines (46.6%) and
lowest in South Korea (7.5%). In another survey of parents of
children with asthma from four Asian countries, most of the
children (73%) had preexisting symptoms of allergic rhinitis
at the time when asthma was diagnosed, and comorbid asthma
and allergic rhinitis substantially affected quality of life and
worsened asthma symptoms.21
Mortality associated with asthma varies from country to
country and seems to be high in countries where access to
essential drugs is low. The Global Initiative on Asthma esti-
mates that approximately 250,000 persons die of asthma an-
nually, and the death rate per 100,000 persons with asthma
aged 5 to 34 years in highly populated China is greater than
10%.22 However, asthma can be controlled with optimal treat-
ment. This has been proven in countries where an asthma
management plan was implemented and the morbidity rate
subsequently decreased.23
Socioeconomic Burden
The annual costs of treating asthma and allergic
rhinitisVboth direct costs (hospitalization, medications) and
indirect costs (time lost from work, premature death)Vare
substantial and represent an even heavier burden in societies
with emerging economies. The Asthma Insights and Reality in
Asia-Paciﬁc survey of urban centers in eight countries in the
Asia-Paciﬁc region showed that the annual per-patient direct
costs ranged from US $108 in Malaysia to US $1010 in Hong
Kong.24 Total per-patient costs, including productivity costs,
ranged from US $184 in Vietnam to US $1189 in Hong Kong.
Urgent care costs were 18% to 90% of the total per-patient
direct costs. The economic burden in the Asia-Paciﬁc region
was higher than that in the United States in relation to the per
capita gross domestic product (13% in the Asia-Paciﬁc region
compared with 2% in the United States) and per capita health
care spending (300% in the Asia-Paciﬁc region compared with
12% in the United States).24,25 Approximately US $20 billion
are spent globally each year in relation to allergic rhinitisVa
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ﬁgure that includes the costs associated with medications,
lost work productivity, and physician consultations. Approxi-
mately US $3 billion are spent in Japan alone.
CONCLUSIONS
The prevalence of chronic allergic respiratory diseases
such as asthma and allergic rhinitis is increasing in the Asia-
Paciﬁc region. With the projected increase in the Asian pop-
ulation over the next decade, the burden of allergic diseases is
expected to increase markedly. The exact mechanisms and de-
termining factors underlying the increase in prevalence re-
main unclear, although allergen sensitization has been found
to be at least as common in the region as in the West. Better
identiﬁcation of triggers and risk factors, increased surveil-
lance of the burden of disease, better public awareness, im-
proved training of physicians and health care personnel, better
access to essential drugs, implementation of environmental
controls, appropriate management, and implementation of pre-
ventive measures26 are key to reducing the burden of these
diseases in the Asia-Paciﬁc region.
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THE WORLDWIDE INCREASE IN ALLERGY
AND ASTHMA
The global prevalence of asthma and the morbidity,
mortality, and economic burden associated with it have in-
creased sharply over the past 40 years, particularly in
children. The prevalence of asthma has increased by 50%
every decade. In North America, an estimated 22.2 million
persons (6.5 million children and 15.7 million adults) have
asthma, and in 2003, asthma accounted for 1.4 deaths per
100,000 persons.1 Asthma is underdiagnosed and under-
treated, although the use of inhaled corticosteroids has had a
positive impact on outcomes.
The increasing number of hospital admissions for
asthma, which are most pronounced in young children, reﬂects
an increase in asthma severity in part because of poor disease
management. Worldwide, approximately 250,000 deaths per
year are attributable to asthma, although overall mortality rates
have decreased since the 1980s. Most asthma deaths occur in
those aged 45 years and older and are largely preventable.
Death is frequently related to inadequate long-term medical
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care (including the lack of affordability in low-income groups)
or to delays in obtaining medical help during an attack.2
The ﬁnancial burden related to asthma in different
western countries ranges from US $300 to US $1300 per
patient per year and disproportionately affects those with the
most severe disease.3 The burden in weaker economies is even
greater. Several signiﬁcant barriers exist to reducing the bur-
den of asthma, particularly in low-income groups, in whom
access to care and essential medications is limited.
Contrary to the global increases seen in recent decades,
some reports have shown no change in asthma trends over the
past decade. Such discrepancies exist even among studies
from the same country. In addition to differences in methods
and the age distribution of the population studied, differences
in the degree of urbanization and in the occurrence and
magnitude of protective (yet only partially identiﬁed) factors
among the study areas may explain these discrepancies. Fur-
thermore, geoclimatic variables and topographic factors, for
example, the altitude at which people live, may also affect the
prevalence of asthma.
Accumulating evidence from some countries, particu-
larly developed countries, indicates that the rising trends in
asthma prevalence among adults may now have plateaued or
even decreased. The data are more contradictory in children.
Several studies have shown stable trends in childhood asthma
since the late 1990s, whereas others have not shown any
change in the steadily rising asthma trends. In contrast, an
upward trend in the prevalence of asthma has been described
in those countries with a previously low prevalence, mainly in
developing countries.4 However, nearly all of these studies
lack the most recent data from the 2000s. Moreover, envi-
ronmental and lifestyle factors may continue to induce asthma
symptoms in susceptible persons until the saturation level in
prevalence, determined by the genetic composition of the
population, is achieved. Defects in environmental Th1 trig-
gering and in inborn Th1 maturation are examples of the
environment- and gene-associated factors that might inﬂuence
asthma prevalence.5 However, severalfold higher peak prev-
alence rates have been reported in Australia, and no peak
prevalence rates have yet been reported in many countries with
high rates of asthma. Because nearly all the studies referred to
here were conducted in afﬂuent westernized countries, no
consideration of the results in light of the East-West gradient
could be performed. It remains to be determined whether the
increased use of antibiotics is involved in the stabilization or
decrease observed, particularly in the prevalence of non-
immunoglobulin E (IgE)Ymediated (sometimes termed non-
atopic) adult asthma, for which an infectious etiology has been
proposed.6 The results of long-term follow-up, derived from
large multinational surveys, including the European Commu-
nity Respiratory Health Survey and International Study of
Asthma and Allergies in Childhood (ISAAC), will be a good
indicator of current asthma trends on a global scale.
The Global Initiative for Asthma7 has outlined a 6-point
patient management plan to address the effective handling of
the increased number of asthma patients receiving primary
care. The plan focuses on patient education, written treatment
plans, and ongoing communication and review between
patients and health care providers. Although the asthma pre-
vention and management programs have undoubtedly
contributed favorably to the reduction in asthma prevalence
in many countries, the possibility that asthma has become
milder, independently of the increased use of inhaled cor-
ticosteroids, cannot be excluded. Furthermore, few studies
have analyzed time trends in the prevalence of IgE-mediated
and nonYIgE-mediated asthma separately. Limited data from
the United Kingdom and Finland indicate that the prevalence
of IgE-mediated allergic asthma has continued to increase
over the past few decades, whereas that of nonYIgE-mediated
asthma has not. This may indicate that the proportions of
IgE-mediated and nonYIgE-mediated asthma within the
overall asthma burden are also changing, which may
additionally explain the ﬁnding that asthma has become
milder. In the Finnish young male population, the prevalence
of asthma increased from 0.29% in 1966 to 1.79% in 1989.8
In the United Kingdom, an evaluation of the prevalence of
asthma in schoolchildren between 1991 and 2002 showed a
signiﬁcant increase in wheezing in the past 12 months and in
severe speech-limiting episodes and night waking, but no
signiﬁcant increase in medical visits because of wheezing.9
Another time trend study also showed a signiﬁcant increase
in physician-diagnosed asthma from 1990 to 2003, which
was more evident in females (range, 7.3%Y14.6%) than in
males (range, 7.8%Y9.4%) in all age groups, particularly in
persons aged 55 years and older.10
PREVALENCE OF ALLERGY AND ASTHMA IN
LOW- AND MIDDLE-INCOME COUNTRIES
In a study that compared the prevalence of asthma and
atopy between children from afﬂuent countries and children
from nonafﬂuent countries, the prevalence of wheezing and
persistent cough was lower in Nigeria than in Australia (10.2%
and 5.1% compared with 21.9% and 9.6%, respectively).11 A
recent report from Ait-Khaled et al12 showed a wide range
of atopic disorders that were prevalent throughout Africa,
with the highest prevalence of current asthma in urban areas
with a higher standard of living (in agreement with the hygiene
hypothesis). However, the prevalence of asthma was also high
in endemic parasite and tuberculosis zones (in opposition to
the hygiene hypothesis).12 In Latin America, the prevalence of
asthma and allergic diseases in childhood was similar to that
in industrialized countries, although the variability was great.13
In a recent survey conducted in Asia, the prevalence of wheez-
ing in rural children from Bangladesh over the previous
12 months was 16%, which was not signiﬁcantly different from
the prevalence observed in other developing regions.14 Taken
together, the evidence shows that the prevalence of asthma
is high and is still increasing slightly, mainly in developing
countries.
OVERCOMING BARRIERS: A GLOBAL
PERSPECTIVE WITH EMPHASIS ON ISAAC
The ISAAC is a unique global epidemiological study of
the prevalence and severity of asthma, rhinitis, and eczema,15
although other studies of trends in the prevalence of symptoms
of asthma, allergic rhinoconjunctivitis and eczema in children
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and adolescents have used similar methods. In the counties of
Troms and Finnmark in Norway, divergent trends in symptom
prevalence were observed. Investigators reported no change in
the prevalence of symptoms of asthma, hay fever, or eczema in
centers in eastern and southwestern Germany, whereas other
investigators reported an increase in the prevalence of hay fever
symptoms, but not that of asthma or eczema, in East Germany.
In Ankara, Turkey, a signiﬁcant decrease in the cumulative
prevalence of allergic rhinitis was noted, with a slight insig-
niﬁcant increase in the prevalence of asthma and eczema.
Tallinn in Estonia was the only center included in the present
study for which trends for asthma, allergic rhinoconjunctivitis,
and eczema had been studied previously. Little change was
reported in the prevalence of wheezing, rhinitis, and itching
rash between cross-sectional studies completed in 1992Y1993
and 1996Y1997. In Aberdeen, United Kingdom, the prevalence
of asthma symptoms plateaued,16 whereas the prevalence of
eczema and hay fever symptoms increased.
The data on trends in symptoms of asthma, allergic
rhinoconjunctivitis, and eczema have direct relevance to health
service delivery in the countries included in the studies and
provide a basis for understanding these disorders. In almost all
participating centers, the prevalence of one or more of the
disorders changed over time. Although changes in the mean
annual prevalence of approximately 0.5% might sound small,
such changes could have substantial public health implications,
especially because the increases took place primarily in heavily
populated countries. Urban centers in developing countries
might have few resources to implement management programs
for these diseases in the face of an overwhelming number of
infectious diseases. The level of interest from centers in devel-
oping countries participating in prevalence studies indicates a
concern that asthma and allergies in children are emerging as
important public health problems.4
The ISAAC has provided valuable data on the prevalence
and severity of asthma, rhinitis, and eczema. The prevalence of
asthma is highest in English-speaking countries, and little
variation exists within English-speaking countries. The over-
all prevalence is higher than expected, particularly in Latin
America. However, variation exists among and within coun-
tries; for example, there is a northwest-southwest gradient
within Europe. The correlation between asthma prevalence and
the gross national product is inconsistent. In some areas (eg,
Germany and China), a major difference in prevalence exists
within the same ethnic group, and a weak and inconsistent
association exists between the prevalence of asthma and that of
other allergic conditions. The ISAAC phase III data suggest an
upward trend in the prevalence of asthma in Argentina. In
Cordoba, the only center that participated in both phases I and
III, the prevalence increased from 11.2% to 11.6%.
In conclusion, prevalence studies, such as ISAAC, that
take into account differentials in variables such as poverty,
population, immigration patterns, and ethnic and cultural dif-
ferences are a major step toward overcoming existing barriers
to the worldwide diagnosis and treatment of asthma.
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HOW ORGANIZATIONS ARE RESPONDING TO
THE GLOBAL INCREASE IN ALLERGIC
RESPIRATORY DISEASE
The incidence of chronic allergic respiratory diseases is
increasing, and a united effort across nations and organizations
is needed to address effectively this global concern.
THE GLOBAL ALLIANCE AGAINST CHRONIC
RESPIRATORY DISEASES
The Global Alliance against Chronic Respiratory Dis-
eases (GARD) is a voluntary alliance of 70 national and in-
ternational organizations, institutions, and agencies working
toward the common goal of reducing the incidence of chronic
respiratory diseases worldwide, according to local needs.1 The
GARD’s vision is Ba world where all people breathe freely.[2
The key aim of GARD is to initiate a comprehensive approach
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to ﬁghting chronic respiratory diseases. The GARD was cre-
ated in recognition of the impact that chronic respiratory dis-
eases have on the global community. Many chronic respiratory
diseases, including asthma and rhinitis, are increasing in prev-
alence, even though these diseases are allergic in origin and are
therefore preventable.
The 53rd World Health Assembly recognized the enor-
mous human suffering caused by chronic diseases and re-
quested the Director General of the World Health Organization
(WHO) to give priority to the prevention and control of these
diseases (WHO resolution 53.17, May 2000; endorsed by all
191WHOMember States). This led to the formation of GARD.
The GARD is being developed in a stepwise approach
using three planning steps that follow the steps outlined in
BPreventing Chronic Disease: A Vital Investment,[ a report
issued by the WHO. To pursue the vision of Ba world where
all people breathe freely,[ GARD’s mission is to develop an
environment that enables sustainable appropriate action at
individual, community, national, and global levels. The goal
of all GARD’s actions is to reduce the chronic respiratory dis-
ease burden globally.3
The GARD’s speciﬁc objectives include the following:
& Developing a standard way of obtaining relevant data on the
risk factors for and disease burden of chronic respiratory
diseases.
& Advocating policies that promote health and disease
prevention in countries worldwide.
& Developing simple and affordable strategies for the diag-
nosis and management of chronic respiratory diseases in all
countries.
& Adapting and tailoring all recommendations to each
country’s health priorities, health care system, diversity of
chronic respiratory diseases, availability of health care per-
sonnel, facilities for diagnosis, and availability and afford-
ability of medications.
In addition, GARD aims to improve coordination
between existing governmental and nongovernmental pro-
grams and to avoid duplication of effort and wastefulness
of resources. Such coordination will also enable participant
organizations to work synergistically to achieve GARD’s
objectives.
GARD WORKING GROUPS
Following a model of collaboration and coordinated
activity, GARD and the World Allergy Organization (WAO)
are working together through established GARD working
groups on major programs in the following four areas: pre-
vention, diagnostics, management, and pediatrics.
Working Group on Health Promotion and
Prevention of Chronic Respiratory Disease
and Allergies
Everyone has the right to live and work in a clean
environment. Exposure to an unhealthy environment can
cause severe and debilitating chronic obstructive pulmonary
disease, asthma, cardiovascular diseases, and cancer. Com-
plete elimination of risk factors is the only way to remove the
risk, and this strategy applies equally to tobacco smoke, indoor
and outdoor air pollutants, occupational hazards, and aller-
gens. This working group will encourage countries to im-
plement policies to reduce the burden of tobacco smoke,
indoor and outdoor pollution, occupational hazards and other
risk factors relevant to chronic respiratory disease.
Working Group on Diagnosis of Chronic
Respiratory Disease and Allergies
The ﬁrst initiative for the Diagnostics Working Group is
to survey WAO Member Societies (national and regional al-
lergy and clinical immunology societies worldwide) to deﬁne
the most relevant allergens in each country. This will enable
the group to ensure the development of low-cost tests for immu-
noglobulinE sensitization against themost common respiratory
andfoodallergens inanycountryor region.Asecondsurveywas
created to obtain information about which in vivo and in vitro
tests are most commonly used worldwide to detect respiratory,
food, and drug allergies.
The Diagnostics Working Group will also conduct
allergy skin prick tests for immunoglobulin E sensitization
using either standardized manufactured allergens (in high- and
middle-income countries) or locally produced reliable extracts
(in middle- and low-income countries). Central to this is the
detection of relevant regional allergens, done in cooperation
with the WAO Emerging Societies Program (see Develop-
ing the Specialty of Allergy Worldwide), which has placed
pollen traps in countries where major airborne allergens need
to be identiﬁed.
Working Group on Control of Chronic
Respiratory Disease and Allergies
The GARD action plans should be tailored to each
country’s needs, priorities, health services, and resources.
& In areas with a high burden of communicable diseases and
a functioning primary health care service, an integrated ap-
proach to prevention, diagnosis, and management is recom-
mended. Models such as the WHOYPractical Approach to
Lung Health will be promoted.
& In areas with a high prevalence of human immunodeﬁ-
ciency virus infection, models such as PALSA Plus (PAL in
South Africa) will be promoted.
& Prevention and care for chronic respiratory disease in
middle- and high-income countries may involve the use of
different models. Disease-speciﬁc approaches can be more
relevant and might target asthma, rhinitis, chronic obstruc-
tive pulmonary disease, and occupational lung diseases.
Approaches will be developed from available management
plans and international guidelines according to country-
speciﬁc needs.
Working Group on Pediatric Chronic Respiratory
Disease and Allergies
Approximately 70% to 80% of asthma in children is
allergic in origin, and 5% to 15% of the global pediatric
population is thought to have asthma.4 The Pediatrics Working
Group believes that future increases in asthma prevalence will
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likely be greatest in the developing world. The group has out-
lined objectives for the diagnosis and management of pediatric
asthma in high-, middle-, and low-income countries. The pri-
orities are to develop an asthma-symptom algorithm to aid
health care practitioners inmaking diagnoses and to provide BIs
it asthma?[ symptom cards, developed by GARD, to facilitate
such diagnoses. Pamphlets and posters will also be developed
to increase awareness about asthma. Emphasis will continue to
be placed on the importance of avoiding tobacco smoke.
Finally, prevalence studies will be conducted in preschool
children.
THE WORLD ALLERGY ORGANIZATON
The WAO is an international umbrella organization with
a membership consisting of 77 regional and national
allergology and clinical immunology societies from around
the world.5 The WAO is a founding member of GARD and is
also one of GARD’s most active and supportive members. The
WAO’s approach is complementary to that of GARD: to ﬁght
allergic diseases worldwide. The WAO is in a unique position
to synthesize the best allergy practices developed by long-
established allergy societies, to disseminate the knowledge
gained throughout diverse geographic regions, and to share
relevant experiences with newer allergy and clinical immunol-
ogy societies and allergists worldwide. In collaboration with
WAO’s member societies, WAO provides direct educational
outreach programs, specialty development programs, sympo-
sia, and lectureships to members in 92 countries. Chronic al-
lergic respiratory disease, which encompasses allergic asthma,
rhinoconjunctivitis, and sinusitis, is a natural focus of interest
for WAO members and thus was selected as the focus of the
joint WAO/GARDWorld Allergy Day 2007.
DEFINING THE SPECIALTY OF ALLERGY AND
THE NEED FOR ALLERGY SERVICES
No studies that provide a complete picture of the size of
the global allergy epidemic have been reported. Figures
available from peer-reviewed studies provide only limited
snapshots of the prevalence of particular allergic diseases in
speciﬁc population subgroups at the time of sampling. In
2005, the WAO Specialty and Training Council conducted an
informal survey of WAO member societies and requested
estimates of the proportion of the population in each country
with allergic disease and estimates of the resources available
to manage these patients. The results, published in 2006,6
included responses from member societies representing 33
countries and suggested that approximately 16,000 trained
allergists serve an estimated total population of 1.3 billion
persons, approximately 22% of whom have some form of al-
lergic disease. The survey conﬁrmed that most allergy patients
are not seen by a trained allergist; therefore, these patients
may not be receiving optimal care. A formal follow-up survey
requested information on the documented prevalence of
asthma, allergic rhinitis, atopic eczema, food allergy, drug
allergy, and Hymenoptera allergy,7 and provides a clearer
picture of the global incidence of speciﬁc allergic diseases.
Studies of anaphylaxis prevalence and anaphylaxis manage-
ment practices are in progress and will be based on inter-
national surveys being conducted by WAO member societies
over the 3-year period from 2007 to 2009.
The ﬁndings from the Allergy Practice Worldwide
Survey guided the development of a WAO position statement,
BRequirements for Physician Competencies in Allergy: Key
Clinical Competencies Appropriate for the Care of Patients
with Allergic or Immunologic DiseasesVA Position State-
ment of the World Allergy Organization.[8 This statement
provides advice for the development of allergy specialist pro-
grams and recommends that appropriately targeted educational
programs be developed for the thousands of nonallergists
worldwide who treat allergy patients.
The new WAO position statement, BWhat Is an Al-
lergist?[ was published in The World Allergy Organization
Journal in January 2008.9 This position statement outlines
what patients and health care providers should expect from
allergy specialists and aims to help physicians refer patients
appropriately to allergists. Further statements on recommen-
dations for training on allergies, at both the undergraduate
level and for pediatric allergists, will be developed during
2008. The WAO position statements have been created to es-
tablish and strengthen the specialty of allergy and to convince
governments and health care systems of the importance of
providing and supporting allergy services.
DEVELOPING THE SPECIALTY OF ALLERGY
WORLDWIDE
The WAO Emerging Societies Program
The WAO Emerging Societies Program encourages the
development of new national allergy societies throughout the
world, particularly in low-income countries. The program is
provided in collaboration with the American College of Al-
lergy, Asthma, and Immunology.While enabling the sharing of
practical experiences and alerting aspiring societies to the cri-
teria required for WAO membership, the program helps to
create local support networks for allergists through partner-
ships with established allergy societies within the same region
and fosters a relationship with WAO. At the same time, the
WAO leadership learns about the challenges and opportunities
faced by colleagues in developing countries. Membership in
WAO enables ﬂedgling societies to become a part of the global
allergy community and to have a voice in WAO’s House of
Delegates, where the societies can help to determine the orga-
nization’s future activities.
TheWAO is planning a network of local summer schools
that will provide hands-on training in allergy diagnostic
techniques and methods of treatment delivery in areas where
allergy services are newly established. In 2008, the Emerging
Societies Program will hold a summer school for primary care
physicians in Latin America, an area where allergy services
are deﬁcient. The summer school will provide training in the
fundamentals of allergy diagnosis and treatment.
The Emerging Societies Program has loaned pollen traps
to centers in Pakistan, Ukraine, and Georgia. These traps are
helping allergists identify the major local airborne pollens and
molds responsible for allergic respiratory diseases in these
countries, and the hope is that the information acquired will
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eventually lead to the availability of appropriately directed di-
agnostic materials and immunotherapy vaccines. The distribu-
tion of more pollen traps is an urgent priority.
Allergy Learning and Educational Programs
The WAO offers a variety of educational and learning
programs that reﬂect the diversity of learning needs within the
global allergy environment. The Global Resources in Allergy
(GLORIA) program provides educational materials in the
form of didactic lectures on major topics in allergy; these
lectures are available on the WAO Web site so that the orga-
nization’s 35,000 members can use the GLORIA materials in
teaching programs.10 The Seminars and Conferences Program
provides invited lecturers to speak at member societies’
meetings on topics selected to speciﬁcally meet the learn-
ing needs of the societies’ local clinical and scientiﬁc allergy
community. In 2007, WAO provided lectures on various
aspects of allergy to more than 25 allergy and clinical
immunology societies throughout the world and will provide
even more in 2008.
To further improve education worldwide, WAO has just
created an online clinical journal, The World Allergy Orga-
nization Journal, to be a major academic resource for the
world’s allergy community.11
Focusing on the knowledge objectives for physicians as
deﬁned by the Specialty and Training Council,8 WAO is also
developing learning programs aimed at meeting the learning
needs of the diverse range of physicians who care for patients
with allergic diseases. A major strategy of this goal is online
education, which is increasingly accessible worldwide and is
a cost-effective way of providing learning and educational
materials asynchronously at a convenient time for global users.
New initiatives for 2008 include a series of 11 online lectures
on the basic immunology underlying allergic disease and a
series of online learning programs based on complex clinical
case histories, through which users are guided through the
wealth of educational materials that are available on the WAO
Web site.
Promoting Allergy Research
The WAO Research Council awards annual short- and
long-term research fellowships enabling junior clinicians to
visit an international expert center to learn a clinical or scien-
tiﬁc technique that is not available at the home institution or to
participate in a research study. These programs aim to help the
students’ home institutions establish new research programs,
and particular emphasis is given to encouraging research in
low-income countries. Fellowships are directed toward three
broad research priorities:
& Genetic factors involved in the development of allergic dis-
ease and response to treatment;
& Allergen characterization and standardization; and
& Clinical and basic studies in allergy and asthma.
Best-Practice Recommendations and Position
Statements
The WAO collaborated with the WHO to develop re-
commendations for the prevention of allergy and allergic
asthma based on the recommendations of a group of inter-
national allergy experts representing all WHO regions. The
document, published in 2004, summarized current knowledge
on the prevention of allergy and allergy-related asthma and
made recommendations for future research to address knowl-
edge gaps.4
The WAO Research Council oversees the creation of
position statements on major topics in allergy. BRecom-
mendations for Standardization of Clinical Trials With Al-
lergen Speciﬁc Immunotherapy for Respiratory Allergy: A
Statement of a World Allergy Organization Taskforce[ was
published in 2007 to ensure that new clinical trials on allergen
immunotherapy are conducted in a standardized way that will
enable worldwide comparability of results.12
The WAO is conducting studies on the current avail-
ability of epinephrine and on the local management of ana-
phylaxis in all member society countries. In parallel with these
studies, the organization is developing global recommenda-
tions on the use of epinephrine for the treatment of
anaphylaxis. Although epinephrine is the drug of choice for
the treatment of anaphylaxis, this drug is not yet globally
available. The hope is that WAO initiatives will assist national
societies in persuading health care funding bodies of the
importance of making epinephrine widely available for the
treatment of anaphylaxis.
Communication
The WAO Web site (www.worldallergy.org) is a major
tool for disseminating education and information. A monthly
e-newsletter reaches more than 26,000 allergists and is avail-
able in eight languages. The newsletter provides reviews on
current scientiﬁc literature and books, updates on WAO
activities, and opportunities for member societies to apply for
educational programs and fellowships. The WAO Web site
contains extensive educational resources and contact informa-
tion and provides links to all WAO member societies’ Web
sites and selected allergy resources on the World Wide Web.
World Allergy Day takes place every two years and is
themed on activities at the biennial World Allergy Congress.
This event provides an opportunity for wider dissemination of
knowledge on major topics in allergic disease, with participat-
ing member societies, local media, and patient groups focus-
ing on those aspects of allergic disease that have the greatest
impact on local communities.
All WAO resources and services are designed to increase
the knowledge and awareness of allergic disease and enhance
the clinical practice of allergy. The WAO’s role is to support
member societies in promoting the specialty at a national level
and to provide information to help in negotiations to obtain
optimal resources for the care of allergy patients. Thus, devel-
opment of the specialty of allergy, physician education and
information, best-practice recommendations, promotion of al-
lergy research, and creation of an awareness of the global
allergy burden are critical responsibilities of WAO. Because of
the enormous global burden of allergic disease, most patients
with allergy will not be seen by an allergist; therefore, non-
allergists must be educated to recognize, diagnose, and treat
patients with uncomplicated allergy and to know when and
how to refer patients with complex disease to an allergist.
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SUMMARY
At a global level, governments and those who fund
health care must be informed about the burgeoning prevalence
of allergic disorders and the likelihood that patient numbers
will continue to increase. Collaboration between GARD and
WAO is of major importance to both organizations in ﬁghting
the global problem of chronic allergic respiratory diseases.
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FUTURE TRENDS IN ALLERGY PREVALENCE AND
TREATMENT: WHAT TO EXPECT?
This section contains a bibliography of general refer-
ences. Further resources and references are provided through
links from the reference list to WAO’s online learning
materials.
How will environmental and social changes inﬂuence
the prevalence of allergic diseases in the global population,
and how will the world need to respond?
FACTORS AFFECTING ALLERGY PREVALENCE
AND TREATMENT
Although the future is difﬁcult to predict, one thing is
certain: change is the only Bconstant.[ Several factors will
affect the future prevalence and treatment of allergy, including
climate change, an increase in industrialization, and the re-
sultant increase in exposure to allergens. A consequence of the
anticipated increase in allergic diseases is that the present
inadequacy in the training of physicians in the diagnosis and
treatment of allergy and asthma must be addressed.
Climate Change
Recently, much attention has focused on climate change
and the impact of climate on allergy. Experts from the World
Health Organization discussed the impact of climate on al-
lergy in May 2007, and numerous articles on this topic have
appeared in the literature and on the Internet.1Y19 Climate af-
fects many aspects of allergy and allergen exposure, including
the type and frequency of allergens in any particular geographic
location, exposure to food and insect allergens, cross-reactivity
among allergens, and the prevalence of allergy-related
diseases.
The world is in the initial stages of a global climate
change that will alter ﬂora and fauna everywhere, creating
changes in the proﬁle of local allergens and potentially
lengthening pollen allergy seasons. As temperatures increase,
plant species are moving into previously temperate regions and
to higher elevations; similarly, when temperatures decrease,
these same plant species may recede back to the original
habitat, whereas other plant species that typically grow only in
colder locales or at higher elevations may spread farther into
previously warmer areas. As warm seasons lengthen, so will
many plant pollination seasons; therefore, human exposure to
allergenic pollens will increase. Increases in temperature will
result in increases in humidity in many places, which in turn
will provide a better environment for mold growth and an
increase in the number of airborne mold spores. Increases in
temperature in desert regions are reducing the amount of fertile
land available for agriculture, which leads to the migration of
large numbers of workers into urban areas. This rural to urban
migration has already been shown to result in an increase in the
number of patients with asthma and allergy symptoms.
Changes in climate will affect crop patterns and increase the
likelihood of new inhalant allergens being introduced into a
locality. In addition, insect species will continue to migrate to
new locations as temperatures increase. Allergies to stinging
insects may increase as new insects are introduced into the
environment, and the number of cockroaches and house-dust
mitesVand thus, the allergen loadVwill increase in accor-
dance with increases in heat and humidity.
Cross-reactivity of allergens currently in the environ-
ment with new allergens that are introduced through plant and
insect migration could result in the development of multiple
immunoglobulin E (IgE) antibodies against these allergens.
This in turn will cause patients to react to more allergens, in-
crease the number of allergy patients, and lead to the devel-
opment of more complex manifestations of allergic disease.
Although attempts to reduce pollution are gaining im-
portance in some parts of the world, pollution is dramatically
WAO Journal & June 2008, Supplement 1 State of World Allergy Report 2008
* World Allergy Organization S13
Copyright @ 2008 World Allergy Organization. Unauthorized reproduction of this article is prohibited.
increasing in other developing areas. To confound this issue,
measures aimed at reducing atmospheric pollution will likely
result in a decrease in the number of patients with chronic
respiratory diseases, such as bronchitis. However, in areas
such as the former East Germany, the number of patients with
allergy-related respiratory diseases reportedly increased as
chronic respiratory diseases decreased.
Allergy has been called Bthe 21st century disease[
because as people live cleaner, healthier, less infection-prone
lives, allergies increase in frequency. A theory on how im-
proved hygiene leads to a shift in immune responses favoring
an allergic-type response has strong scientiﬁc support. Thus,
as the world develops to a more industrialized less agricultu-
rally based economy, allergies will continue to increase and
plague those very areas where lifestyles are improving.
Dietary Changes Caused by Industrialization
Allergy clinicians are seeing an epidemic of food
allergies in developed countries.20,21 Up to 10% of children
in the United States and Europe will develop food allergies
during the ﬁrst decade of life, with the highest incidence in the
ﬁrst one or two years of life. A reduction in breast-feeding by
working mothers has led to an increase in exposure at an early
age to foreign proteins such as those in cow’s milk. Moreover,
these bottle-fed babies are ingesting foreign proteins that
would ordinarily be broken down by the mother’s digestive
and immune system during the formation of breast milk.
Greater use of processed foods and preservatives may also
increase the exposure to more allergenic proteins. Genetic
modiﬁcation of food can introduce an allergen into a previously
Bsafe[ food, rendering the food allergenic to those who are
sensitized to the modifying protein.
Decreases in the Number of Trained Physicians
for the Projected Increase in Allergy Patients
Estimates indicate that up to 20% to 25% of the pop-
ulation of every developed nation will develop some form of
allergic disease.22,23 As countries develop more comfortable
lifestyles and life-threatening infections are eliminated, al-
lergies not only will continue to increase, but will affect this
increasing segment of the population for a lifetime and lead to
increased losses in productivity both at school and in the
workforce, and thereby result in greater costs to society. With
further reductions in breast-feeding and increases in exposure
to processed food, food allergies will become more serious and
more widespread. Accurate diagnosis and treatment of IgE-
mediated food allergy will become ever more important. As
the ThirdWorld moves to the First World and as the prevalence
of allergy increases globally, the need for more allergy prac-
titioners and new allergy treatments will increase.
Clearly, there are not enough allergists to diagnose and
treat the projected increased number of patients with allergy.24
This shortage of appropriately trained health care providers is
compounded by the fact that in many highly industrialized
countries, the overall rising costs of health care have dictated
a reduction in the specialty care provided by allergists, with
the expectation that allergy can be treated adequately by
family practitioners. Many patients with allergies are treated by
physicians who have had an extremely limited exposure to
allergy diagnosis and treatment during medical school and
postgraduate training.
The WAO, speaking for all 77 allergy and immunology
member societies worldwide, has just published two position
statements addressing these issues: the ﬁrst, BWhat Is an
Allergist,[25 deﬁnes the special clinical skill sets of a trained
allergist; the second, BRequirements for Physician Competen-
cies in Allergy: Key Clinical Competencies Appropriate for
the Care of Patients With Allergic or Immunologic Dis-
eases,[26 delineates exactly what training is required for
physicians at all levels to care competently for allergy patients.
The WAO Specialty and Training Council is now developing a
recommended training syllabus in Allergy and Clinical
Immunology to provide a standardized basic curriculum that
can be adapted for local use around the world. The hope is that
the governing bodies of the world’s medical communities will
attend to these position statements and not only recognize
the current and future deﬁciencies in the numbers of well-
trained allergists, but also encourage specialty training in al-
lergy diagnosis and treatment on a more local level. NewWAO
initiatives will address the importance of including allergy and
clinical immunology in undergraduate medical training and of
the special skill sets required for physicians treating children
with allergic diseases.
CHANGES IN ALLERGY TREATMENTS
Antihistamines
Oral antihistamines have traditionally been the ﬁrst-line
therapy for rhinoconjunctivitis and allergic skin conditions.
Histamine is at least partly responsible for most or all of the
primary symptoms of allergy, both in the mucosa of the nose
and eyes and in the skin. Countless patients worldwide have
beneﬁted from the use of oral antihistamines, which reduce
sneezing, itching, and rhinorrhea. In recent years, newer non-
sedating antihistamines have become available and are rec-
ommended because these agents cause less sedation, have
more selective mechanisms of action, and are longer lasting.
Because oral antihistamines are accepted and are available
worldwide, these drugs will likely remain the standard treat-
ment of choice for allergic diseases, and the use of nonsedat-
ing antihistamines will likely increase. Nasal antihistamine
sprays have also become available more recently and are very
effective. In the future, both oral and nasal antihistamines will
likely be used to treat rhinitis, and oral antihistamines will
likely be used to treat cutaneous disorders.27,28
Corticosteroids
Recognition that topical corticosteroids are the most
effective treatments available for rhinitis and asthma should
lead to an increase in the use of these drugs for the treatment
of these diseases worldwide. Some of the mature corticoster-
oid products are very inexpensive; therefore, well-trained
practitioners can prescribe these modern medicines even in
regions where resources are limited.
The WAO anticipates that the emphasis will likely be to
use more topical rather than systemic treatments for rhinitis
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and asthma. The combination of topical nasal corticosteroids
and antihistamines actually potentiates the activity of each drug
in the treatment of rhinitis, and such a combination product,
once marketed as a dual-acting nasal spray, is likely be the
preferred choice for treating both allergic and nonallergic
rhinitis. Surgical treatment of sinusitis will inevitably become
less popular as the understanding of this condition increases
and effective treatments, including corticosteroids developed
in vehicles that allow instillation within the sinuses, become
more widely available.29Y31
Predictably, the medications currently used to treat al-
lergy may not all be used in the future. Many modern med-
ications are cost prohibitive and are therefore unavailable to
much of the world. Future advances in pharmaceuticals may
provide relatively inexpensive treatments, which will be par-
ticularly cost effective if used appropriately by both clinicians
and patients.
Immunomodulation
Modulation of the immune system to decrease the pro-
duction of IgE, and thereby reduce the incidence of allergic
disease, should become a reality. In contrast, immunomodula-
tion to increase the production of IgG might help prevent
infectious diseases in patients with IgG deﬁciencies.
Allergen Immunotherapy
Allergen immunotherapy has become highly standard-
ized as allergens have become characterized, which ensures an
accurate diagnosis and treatment with the speciﬁc allergen to
which patients are sensitized.32,33 Comparative data indicate
that allergen immunotherapy is a potent long-term treatment
capable of reducing the severity of allergic rhinitis and asthma.
Data indicate that the use of immunotherapy to treat children
with allergic rhinitis reduces the subsequent development of
asthma. Thus, allergen immunotherapy should be considered
for the long-term management of appropriately selected al-
lergic patients.
Traditionally, allergen immunotherapy has been admin-
istered via subcutaneous injection. Support for this preferred
route of administration is based on 100 years of experience and
the results of a multitude of studies on the use of high-dose
subcutaneous injection therapy. An alternative form of immu-
notherapy is the sublingual administration of allergen, the ef-
fectiveness of which has been demonstrated in European
patients with rhinitis caused by certain allergens, such as grass
and house-dust mite. Sublingual immunotherapy has become
the preferred treatment of some allergic patients in Europe.
Studies examining the efﬁcacy of this treatment in other pop-
ulations are underway. Because sublingual immunotherapy
is self-administered, a strong likelihood exists that this ther-
apy will be preferred by patients once proven and approved
throughout the world.
Immunotherapy is the only current treatment that has
long-term beneﬁts, that is, effects that last beyond the period
of active treatment. Studies have clearly shown that effective
allergen immunotherapy can have protective effects that last for
years after treatment has ended. Thus, immunotherapy can re-
duce allergic rhinoconjunctivitis and asthma, can reduce the
development of asthma in treated patients, can produce effects
that last for years after the completion of a successful pro-
gram, and may become available as sublingual drops for some
patents. An increased use of immunotherapy in the future
seems likely. However, well-trained practitioners are essential
to ensure the accurate identiﬁcation of the causative allergen or
allergens, to determine when sublingual immunotherapy
should be used, to ensure patient safety, and to select allergens
that are appropriate to the patient.
Biotechnology
Monoclonal antibodies against IgE and the various cy-
tokines and mediators involved in the allergic cascade are
being extensively researched.34Y36 A humanized monoclonal
antibody against IgE is already available for use in adults
and adolescents with moderate to severe allergic asthma and
may soon be indicated for use in children. Studies are under-
way to determine the full range of atopic conditions for
which monoclonal anti-IgE therapy may be efﬁcacious. Cost
considerations and the availability of trained allergists to de-
termine the patients for whom this type of therapy will be
effective will initially determine the global availability of this
class of treatments.
Epinephrine
Anaphylaxis is an acute life-threatening condition that
affects about 1% of the population of most developed coun-
tries. More than 200 patients are estimated to die of anaphy-
laxis in the United States each year. Autoinjected epinephrine
(adrenaline) is an extremely effective treatment of acute ana-
phylaxis because this drug reverses all of the life-threatening
processes involved in a matter of minutes.37,38 Practitioners in
countries where this therapy is licensed can readily provide
epinephrine-containing devices to patients at risk for anaphy-
laxis from stinging insects, food allergies, and other causes of
anaphylaxis.
The fact that many countries still do not license epi-
nephrine injectors for prescription purposes is amazing. The
WAO’s leadership believes that autoinjectors of epinephrine
need to becomemorewidely available and that physicians need
to be instructed in how and when to use these injectors for
the treatment of anaphylaxis. In countries where epinephrine
autoinjectors are available, anaphylaxis can be successfully
managed by patients who are trained to use these devices cor-
rectly. However, epinephrine injectors should be prescribed
only by practitioners with the knowledge to: accurately
diagnose the symptoms of anaphylaxis, diagnose the causative
allergens, advise patients on strategies to avoid the offending
allergen, and train patients in the proper use of this life-saving
treatment. Recognizing, even in 2007, that self-injectable
epinephrine devices are still not available in many countries
with huge populations, WAOwill continue to campaign for the
global availability of this essential therapy.
DISEASE MANAGEMENT GUIDELINES
As the incidence and importance of asthma and other
allergies increase around the world, treatment guidelines
developed in conjunction with WAO member societies will
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become even more important.29,39 These guidelines will
provide a broad framework for treatment that can be used in
all communities once suitable treatments become widely
available.
CONCLUSIONS
The prevalence of all types of allergic diseases, such as
allergic rhinoconjunctivitis, asthma, sinusitis, food allergies,
and anaphylaxis is increasing. Health care resources are not
increasing commensurately, and the number of physicians
trained to diagnose and treat allergic diseases is insufﬁcient.
Resources can be maximized by increasing the number of
physicians trained to treat allergic diseases and by implement-
ing and encouraging compliance with guidelines for the treat-
ment of these diseases. The need for new allergy medications,
new forms of treatment delivery, and worldwide access to li-
censed allergy medications is urgent.
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